熱門資訊> 正文
报道称，蒂瓦因贬低Copaxone竞争对手而面临欧盟罚款
2024-09-11 00:51
- Teva (NYSE:TEVA) is facing a fine by EU regulators for allegedly disparaging a product that competes with its multiple sclerosis drug Copaxone, according to Reuters.
- Reuters said the move highlights the EU’s concern that such practices undermine competition in the pharmaceutical industry. It noted that the company was charged by the European Commission in 2022 for engaging in anticompetitive practices over Copaxone.
- The European Commission declined to comment on the matter, while Teva did not immediately respond to requests for comment, Reuters added.
More on Teva Pharmaceutical
- Cheap Teva Stock Should Reward Patient Investors
- Teva Pharmaceutical Industries Limited (TEVA) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
- Teva's Transformation: From Generics Leader To Branded Drug Innovator
- Teva Pharmaceutical hits a new 52-week high
- Teva gains after lifting outlook on YTD performance
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
